Gemzar Articles
NICE on gemcitabine for pancreatic cancer
11 May 2001
Recent Japanese drug approvals for multinationals
24 April 2001
Euro NSCLC market sees renewed growth
21 March 2001
Zyprexa takes over as Eli Lilly's top seller
26 January 2001
Sanofi-Synthelabo sales up 11.4%
25 October 2000
New products boost growth at Eli Lilly
20 October 2000
Eli Lilly's 2nd-qtr EPS increases 17%
25 July 2000
NICE reviewing Gemzar and Temodal
21 July 2000
British Biotech loses again with marimastat
23 June 2000
Aphton to begin Ph III in pancreatic cancer
18 April 2000
Earnings rise 18% at Eli Lilly
17 April 2000
Stock Commentary Europe
3 February 2000
Eli Lilly 4th qtr net income up 39%
28 January 2000
AVI Biopharma starts pivotal trial of Avicine
24 December 1999
BB's marimastat data delayed, expected early next year
22 November 1999
Eli Lilly suffers from poor Prozac sales
22 October 1999
British Biotech to look for partners
1 July 1999
Beyond Prozac : Lilly outlines future
14 June 1999
Sanofi, Lilly to develop oxaliplatin in USA
20 April 1999
Stock Commentary New York
29 March 1999
British Biotech drops Zacutex and restructures business
26 March 1999
Marimastat study sparks drop in share price of British Biotech
16 February 1999
Marimastat study sparks drop in share price of British Biotech
15 February 1999
PMC/Aphton's Gastrimmune In PIII
23 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Imutec's Virulizin Phase I/II Results
1 September 1998
FDA Approves Gemzar For NSC Lung Cancer
27 August 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Onconase Dropped For Pancreatic Cancer
17 July 1998
British Biotech Hit By Broker Warning
15 June 1998
Cancer Market Growth Forecasts To 2010
15 June 1998
Cancer: New Therapeutics, And Quality Of Life
30 April 1998
US Quarterly Financial Results Round-Up
23 April 1998
Xeloda NDA Backed By FDA Advisory Panel
20 March 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
US 3rd Quarter Results Show Strong Growth
22 October 1997
Smaller US Firms' Losses Grow Due To R&D Costs
31 July 1997
Strong Dollar Impact On Eli Lilly
5 May 1997
Pharma Strategies: M&A Or Technical Excellence?
3 March 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Gemzar In NSCLC
27 January 1997
US Quarterly Results Show Improvements
4 November 1996
Eli Lilly Investing In Brazil
23 September 1996
Alfacell Begin Comparison Phase III With Onconase And Lilly's Gemzar
2 September 1996
Lilly Signs $100 Million Antibiotic Deal With Dura
2 September 1996
Lilly Cuts Costs As It Launches New Products
15 July 1996
New York Stock Comment
3 June 1996
New York Stock Comment
27 May 1996
Marimastat Fulfills All Expectations At ASCO
27 May 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
NEW YORK STOCK COMMENT
2 October 1995
US FDA Approving Fewer NMEs, But Faster, In 1995
11 September 1995
Lilly's Gemzar Moves Closer To US Market
31 July 1995
Lilly's Gemzar Cleared In Scandinavia
3 July 1995
FDA Grants Treatment IND For Lilly's Gemcitabine
27 February 1995
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
